Our study demonstrates that combining MIR4435-2HG with another lncRNA, CASC15 (Cancer Susceptibility Candidate 15), enables the stratification of ESCC patients into distinct molecular subtypes with varying clinical outcomes. This evidence concerns the gene CASC15 and cancer.